scholarly journals A screening tool to identify risk for bronchiectasis progression in children with cystic fibrosis

2021 ◽  
Author(s):  
Daan Caudri ◽  
Lidija Turkovic ◽  
Nicholas H de Klerk ◽  
Tim Rosenow ◽  
Conor P. Murray ◽  
...  
2016 ◽  
Vol 116 (5) ◽  
pp. 813-818 ◽  
Author(s):  
Miriam Isabel Souza dos Santos Simon ◽  
Gabriele Carra Forte ◽  
Juliane da Silva Pereira ◽  
Elenara da Fonseca Andrade Procianoy ◽  
Michele Drehmer

2019 ◽  
pp. 174239531988118
Author(s):  
Virginia Quick ◽  
Grace Chang

Objectives To investigate health care providers’ perspectives on their experiences and practices with cystic fibrosis patients exhibiting disordered eating behaviors and their recommendations for interventions and screening of this population. Methods Experienced health care providers (N = 17) were recruited from the Cystic Fibrosis Foundation listserv to participate in a semi-structured interview via phone. Two trained qualitative researchers independently coded audio-recorded interview scripts. Major themes were generated from questions inquiring health care providers’ perspectives on their experiences and practices with cystic fibrosis patients exhibiting disordered eating behaviors and their recommendations for better interventions and screening of disordered eating. Results The most prominent disordered eating behaviors observed by health care providers in cystic fibrosis patients were misusing pancreatic enzyme medication (53%), food restriction behaviors (47%), binge eating (29%), and skipping meals (29%). Over half (53%) of health care providers reported not having policies or procedures for disordered eating of cystic fibrosis patients. All health care providers thought it would be beneficial to have a cystic fibrosis-specific disordered eating screening tool. Recommendations by health care providers included developing a national standard protocol for cystic fibrosis disordered eating and educational training for health care providers. Discussion Ongoing development of evidence-based guidelines for screening and treating disordered eating among cystic fibrosis patients is warranted including development of a cystic fibrosis-specific disordered eating screening tool.


2005 ◽  
Vol 39 (2) ◽  
pp. 103-107 ◽  
Author(s):  
L. Dobson ◽  
A. Stride ◽  
C. Bingham ◽  
S. Elworthy ◽  
C.D. Sheldon ◽  
...  

2016 ◽  
Vol 15 (2) ◽  
pp. 258-260 ◽  
Author(s):  
Valérie Boudreau ◽  
Adèle Coriati ◽  
Katherine Desjardins ◽  
Rémi Rabasa-Lhoret

PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0250036
Author(s):  
Amy Darukhanavala ◽  
Filia Van Dessel ◽  
Jannifer Ho ◽  
Megan Hansen ◽  
Ted Kremer ◽  
...  

Background Cystic fibrosis (CF) leads to pancreatic endocrine dysfunction with progressive glycemic disturbance. Approximately 30%–50% of people with CF eventually develop CF–related diabetes (CFRD). Pre-CFRD states progress from indeterminant glycemia (INDET) to impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). Screening guidelines recommend inconvenient annual 2-hour oral glucose tolerance tests (OGTTs), beginning at age 10 years. More efficient methods, such as hemoglobin A1C (HbA1c), have been evaluated, but only limited, relatively small studies have evaluated the association between HbA1c and pre-CFRD dysglycemic states. Objective To determine whether HbA1c is an appropriate screening tool for identifying patients with pre-CFRD dysglycemia to minimize the burden of annual OGTTs. Methods This retrospective review evaluated medical records data of all University of Massachusetts Memorial Health System CF patients with an HbA1c result within 90 days of an OGTT between 1997 and 2019. Exclusion criteria were uncertain CF diagnosis, other forms of diabetes, or incomplete OGTT. In total, 56 patients were included and categorized according to OGTT results (American Diabetes Association criteria): normal glucose tolerance, INDET, IFG, or IGT. Associations were evaluated between HbA1c and OGTT results and between HbA1c and pre-CFRD dysglycemic states. Results Mean HbA1c was not significantly different between patients with normal glucose tolerance and those in the INDET (p = 0.987), IFG (p = 0.690), and IGT (p = 0.874) groups. Analysis of variance confirmed the lack of association between HbA1c and glycemia, as mean HbA1c was not significantly different amongst the four categories (p = 0.250). Conclusion There is increasing awareness of the impact of pre-CFRD states, including reduced pulmonary function and nutritional status. Unfortunately, our results do not support using HbA1c as a screening tool for pre-CFRD dysglycemia, specifically INDET, IFG, and IGT. Further studies are warranted to evaluate more efficient screening methods to reduce the burden of annual OGTTs.


2015 ◽  
Vol 14 ◽  
pp. S105 ◽  
Author(s):  
M. Nicolo ◽  
D. Dorgan ◽  
M. Ferrin ◽  
D. Holsclaw ◽  
S. Smith ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document